Latest news with #CulverCity
Malay Mail
4 days ago
- Entertainment
- Malay Mail
James Gunn's ‘Superman' is the fresh new restart we didn't know we needed
JULY 19 — As an 80s kid, Superman was a major pop culture character during my childhood years. The first two Superman movies, directed by Richard Donner and Richard Lester respectively and starring Christopher Reeve, were huge staples of my TV and VHS viewing diet back then. They were exactly what the kid in me wanted and needed in a superhero film, although a case can clearly be made that there really weren't that many of those back then. Director James Gunn and cast members David Corenswet, Rachel Brosnahan, and Nicholas Hoult pose at a photo call for the film Superman in Culver City, California June 28, 2025. — Reuters pic I don't remember much about Superman III and Superman IV, both of which I remembered as just being much goofier than the first two films (which were already goofy, in case you don't remember!) and had a very memorable Richard Pryor in one of them. I also remember liking both reboots that came much later on, Bryan Singer's Superman Returns and Zack Snyder's Man Of Steel, both very different in tone and style from each other (as they are from the originals), yet with plenty of fresh new perspectives and flavours brought into a legendary and decades old comic book property. As open as I was to both reboots back then, that same open mindset was also what I brought with me to the screening of the new Superman movie, this time directed by James Gunn (of the Guardians of the Galaxy fame). I know that the internet is awash with insults and war of words between fans of Snyder's version of Superman and Gunn fans, but as someone who's enjoyed every screen iteration of the Superman character so far, I was looking forward to what this new one might offer differently from the ones that came before it. Within just the first few seconds of the film, which opens with intertitles explaining what's been happening in the film's world, with the last sentence of said intertitles casually mentioning that Superman had just lost his first ever fight, the audience is thrown straight into what would usually be the middle of a Superman film. There's no origin story here, we're just thrown straight into the story, just like how we'd go straight into an issue's particular story when we open a comic book. This is a Superman story where Superman (David Corenswet absolutely nailing the role as both Superman and Clark Kent) is a lot more 'man' than the 'super' that we've been used to seeing all these years. Gunn makes us believe this by gifting us with the scariest Lex Luthor (Nicholas Hoult giving a brilliantly angry and unhinged performance) that we've seen yet in a Superman film, and since we're meeting all these characters in media res, he's already had years of spending his riches trying to figure out how to beat Superman, and that sense of jeopardy is right there from the film's very beginning all the way to the end, as Superman faces all manner of batterings, broken bones and bruises, courtesy of Luthor's dastardly machinations. For those who miss the goofier and cornier parts of Luthor from the first two Superman movies, fear not, as that part of the equation is performed to perfection by the always goofy Miss Eve Teschmacher (played here by Sara Sampaio), his girlfriend. And let's not forget Clark Kent's circle of friends like Jimmy Olsen (Skyler Gisondo), his love interest Lois Lane (Rachel Brosnahan), Green Lantern Guy Gardner (a hilarious Nathan Fillion), Mr Terrific (Edi Gathegi stealing the show) and of course, the movie's trump card, his dog Krypto, all of whom provide the film with Gunn's trademark brand of lighthearted fun. In between all this is Superman's fierce commitment to doing good, and to being a good human, in the face of all sorts of injustice and prejudice, and it's in this internal battle as he tries to uphold the principles of justice in the face of the sometimes fascist establishment that this new Superman movie really takes flight. He goes out of his way to save helpless people, kids and even animals when battling evil or alien forces, and he even insists on trying to find the most humane way to deal with a giant kaiju threatening his beloved Metropolis, which in short shows that this iteration of Superman wants nothing more than to do the right thing. If that means ignoring international law to stop a nation with a well-equipped army from invading a nation of defenseless people living behind a fence (with only sticks and rocks as weapons to defend themselves against the invasion), with genocide surely an unavoidable outcome of their plans, then so be it, because he believes that it is the right thing to do. The fact that this scenario mirrors what's been happening in our real-world geopolitics right now can only add value to what is still very much a popcorn comic book movie. It feels much 'smaller' in scale than the previous Superman movies, but in trying to make a more comic book accurate movie, I guess that's also another achievement unlocked for this more colourful, more lighthearted, more fun, but clearly not more shallow version of a Superman story. It's definitely not a masterpiece, but it's damn good fun! * This is the personal opinion of the columnist.
Yahoo
6 days ago
- Business
- Yahoo
Snail, Inc. Announces Intent to Explore Proprietary USD-Backed Stablecoin
Culver City, United States, July 16th, 2025, ChainwireSnail, Inc. (Nasdaq: SNAL) ('Snail Games' or the 'Company'), a leading global independent developer and publisher of interactive digital entertainment, announced its intention to explore pursuing a strategic digital asset initiative that includes the evaluation and feasibility for introduction of its own proprietary stablecoin. This initiative would be subject to a range of factors, including but not limited to, regulatory approvals, market conditions, technical feasibility, cybersecurity safeguards, financial controls, and internal governance. The Company believes that exploring stablecoin infrastructure may position it as an early mover within the digital entertainment industry. While no decisions have been made to integrate such technology into the Company's corporate strategy, it continues to evaluate and explore opportunities as part of its broader innovation roadmap. Recognizing the growing potential of crypto-based transactions in the digital entertainment and gaming industry, the Company is currently assessing the feasibility of developing and exploring its stablecoin with multiple external use cases, with no current timeline or commitment. To support this initiative, Snail Games has retained Dr. George Cao, an external consultant. Dr. Cao earned his PhD degree in Computer Science from the University of Chicago and is the Founder and the Chief Executive Officer of AscendEX, a full-stack cryptocurrency financial platform that offers simple solutions for investing, trading, and earning to global users. In addition, the Company also retained seasoned legal advisors, including a nationally recognized law firm ranked by Chambers FinTech Legal USA as a leading firm serving cryptocurrency and blockchain clients. 'This stablecoin exploration is a natural evolution of our innovation-led strategy and will support a broader effort to evaluate how blockchain-based technologies could be aligned with the Company's long-term goal to be at the forefront of digital transformation in the entertainment space,' said Snail, Inc. co-CEO Hai Shi. 'To support this initiative, we've engaged a nationally recognized law firm and a seasoned strategic advisor to support and guide the successful exploration of this opportunity. We are evaluating potential future phase hiring needs for professionals with specialized experience in blockchain, stablecoins, and digital asset strategy. While our focus continues to remain on gaming across our ARK franchise, indie titles, and other up-and-coming genres, this investigation into the crypto space and evaluation of the feasibility of launching our own stablecoin would mark a key step in advancing our vision of driving innovation across digital entertainment. We're excited to share continued updates as we reach meaningful milestones in our evaluation.' About Snail, Inc. Snail, Inc. (Nasdaq: SNAL) is a leading, global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs, and mobile devices. For more information, users can visit: Forward-Looking Statements This press release contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this press release can be identified by the use of forward-looking words such as "anticipate," "believe," "could," "expect," "should," "plan," "intend," "may," "predict," "continue," "estimate" and "potential," or the negative of these terms or other similar expressions. Forward-looking statements appear in a number of places in this press release and in our public filings with the SEC and include, but are not limited to, statements regarding (i) the evaluation and feasibility for introduction of Snail's own proprietary stablecoin and any future implementation, which will depend on multiple factors, including regulatory considerations, technical readiness, risk assessments and strategic alignment with Snail's core business, (ii) Snail as a pioneer among public companies within the digital entertainment industry to integrate stablecoin infrastructure directly into its corporate strategy, (iii) Snail showcasing its ongoing commitment to fostering creativity and innovation across its global portfolio, (iv) Snail's long-term investment in the next generation of gamers and creators, and (v) Gen Alpha projected to become the most digitally fluent and commercially influential generation to date. You should carefully consider the risks and uncertainties described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was filed by the Company with the SEC on March 26, 2025 and other documents filed by the Company from time to time with the SEC, including the Company's Forms 10-Q filed with the SEC. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based. Disclaimer: This press release does not constitute an offer, sale or solicitation of an offer to buy any digital asset or security. The Company has not committed to a specific launch timeline or use case deployment. Any future implementation will depend on multiple factors, including regulatory considerations, technical readiness, risk assessments and strategic alignment with Snail's core business. Snail may determine at any time to abandon its current intent to explore the issuance of A proprietary US dollar-backed stablecoin. Investor Contact: John Yi and Steven Shinmachi Gateway Group, Inc. 949-574-3860 SNAL@ ContactMonty RoblesSnail Gamesmontyr@ | © Copyright 2025 All rights reserved Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
15-07-2025
- Business
- Globe and Mail
Snail, Inc. Announces Intent to Explore Proprietary USD-Backed Stablecoin
CULVER CITY, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Snail, Inc. (Nasdaq: SNAL) ('Snail Games' or the 'Company'), a leading global independent developer and publisher of interactive digital entertainment, announced its intention to explore pursuing a strategic digital asset initiative that includes the evaluation and feasibility for introduction of its own proprietary stablecoin. This initiative would be subject to a range of factors, including but not limited to, regulatory approvals, market conditions, technical feasibility, cybersecurity safeguards, financial controls, and internal governance. The Company believes that exploring stablecoin infrastructure may position it as an early mover within the digital entertainment industry. While no decisions have been made to integrate such technology into the Company's corporate strategy, it continues to evaluate and explore opportunities as part of its broader innovation roadmap. Recognizing the growing potential of crypto-based transactions in the digital entertainment and gaming industry, the Company is currently assessing the feasibility of developing and exploring its stablecoin with multiple external use cases, with no current timeline or commitment. To support this initiative, Snail Games has retained Dr. George Cao, an external consultant. Dr. Cao earned his PhD degree in Computer Science from the University of Chicago and is the Founder and the Chief Executive Officer of AscendEX, a full-stack cryptocurrency financial platform that offers simple solutions for investing, trading, and earning to global users. In addition, the Company also retained seasoned legal advisors, including a nationally recognized law firm ranked by Chambers FinTech Legal USA as a leading firm serving cryptocurrency and blockchain clients. 'This stablecoin exploration is a natural evolution of our innovation-led strategy and will support a broader effort to evaluate how blockchain-based technologies could be aligned with the Company's long-term goal to be at the forefront of digital transformation in the entertainment space,' said Snail, Inc. co-CEO Hai Shi. 'To support this initiative, we've engaged a nationally recognized law firm and a seasoned strategic advisor to support and guide the successful exploration of this opportunity. We are evaluating potential future phase hiring needs for professionals with specialized experience in blockchain, stablecoins, and digital asset strategy. While our focus continues to remain on gaming across our ARK franchise, indie titles, and other up-and-coming genres, this investigation into the crypto space and evaluation of the feasibility of launching our own stablecoin would mark a key step in advancing our vision of driving innovation across digital entertainment. We're excited to share continued updates as we reach meaningful milestones in our evaluation.' About Snail, Inc. Snail, Inc. (Nasdaq: SNAL) is a leading, global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs, and mobile devices. For more information, please visit: Forward-Looking Statements This press release contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this press release can be identified by the use of forward-looking words such as "anticipate," "believe," "could," "expect," "should," "plan," "intend," "may," "predict," "continue," "estimate" and "potential," or the negative of these terms or other similar expressions. Forward-looking statements appear in a number of places in this press release and in our public filings with the SEC and include, but are not limited to, statements regarding (i) the evaluation and feasibility for introduction of Snail's own proprietary stablecoin and any future implementation, which will depend on multiple factors, including regulatory considerations, technical readiness, risk assessments and strategic alignment with Snail's core business, (ii) Snail as a pioneer among public companies within the digital entertainment industry to integrate stablecoin infrastructure directly into its corporate strategy, (iii) Snail showcasing its ongoing commitment to fostering creativity and innovation across its global portfolio, (iv) Snail's long-term investment in the next generation of gamers and creators, and (v) Gen Alpha projected to become the most digitally fluent and commercially influential generation to date. You should carefully consider the risks and uncertainties described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was filed by the Company with the SEC on March 26, 2025 and other documents filed by the Company from time to time with the SEC, including the Company's Forms 10-Q filed with the SEC. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based. Disclaimer: This press release does not constitute an offer, sale or solicitation of an offer to buy any digital asset or security. The Company has not committed to a specific launch timeline or use case deployment. Any future implementation will depend on multiple factors, including regulatory considerations, technical readiness, risk assessments and strategic alignment with Snail's core business. Snail may determine at any time to abandon its current intent to explore the issuance of A proprietary US dollar-backed stablecoin.
Yahoo
08-07-2025
- Business
- Yahoo
UK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
ANKTIVA, a first-in-class, lymphocyte-stimulating agent, works synergistically with BCG to activate and proliferate natural killer (NK) and T cells, helping eliminate cancer Already approved in the U.S. and designated as a Breakthrough Therapy by the FDA, this marks ANKTIVA's first marketing approval outside the U.S. ANKTIVA plus BCG offers a new option for eligible patients among the 16,400 to 18,000 people diagnosed with NMIBC in the UK each year1 CULVER CITY, Calif., July 08, 2025--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of certain bladder cancer patients. This is the first marketing approval outside the U.S. for this novel lymphocyte-stimulating agent. "With the MHRA's authorization of ANKTIVA plus BCG, we can now offer our immunotherapy outside the U.S. to help patients with a disease that, if not effectively treated, can lead to bladder removal," said Dr. Patrick Soon-Shiong, Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. "This immune-boosting, lymphocyte-stimulating agent, the first of its kind, is central to our Cancer BioShield platform, which is designed to restore immune function and support long-term disease control." "ImmunityBio is honored to have received this important authorization from the UK MHRA. In light of the United States Most-Favored-Nation Prescription Drug Pricing policy implemented on May 12, 2025, we are actively evaluating our go-to-market strategy for the UK," said Richard Adcock, CEO and President of ImmunityBio. ANKTIVA is a first-in-class IL-15 agonist that activates and proliferates natural killer (NK) cells and CD4+ and CD8+ T cells. It is designed to restore immune competence by reversing lymphopenia—a condition in which cancer and conventional therapies, such as chemotherapy, radiation and checkpoint inhibitors, reduce the number and function of immune cells. Restoring immune function is essential for immunosurveillance, immunogenic cell death, and sustained tumor control. The BioShield platform's effectiveness can be monitored using a routine complete blood count (CBC). ANKTIVA was designated a Breakthrough Therapy by the FDA and received approval from both the FDA and MHRA based on its safety and efficacy outcomes of complete response (CR) and duration of response (DOR). In a single-arm, multicenter trial, 77 evaluable patients received ANKTIVA with BCG for up to 37 months. As of the November 2023 data cutoff, the duration of complete response for some patients exceeded 47 months and remains ongoing. These extended duration of complete responses beyond 24 months with ANKTIVA and BCG surpasses the benchmark for meaningful clinical results set by experts from the International Bladder Cancer Group. ImmunityBio has also submitted regulatory applications to the European Medicines Agency (EMA) to expand availability of ANKTIVA across the 27 European Union (EU) member states, as well as Iceland, Norway and Liechtenstein. About NMIBC CIS Bladder cancer is the 10th most commonly-diagnosed cancer globally,2 and in the UK, the Action Bladder Cancer UK estimates approximately 23,000 patients are diagnosed annually.1 At the time of diagnosis, about 80% of cases are non-muscle invasive bladder cancer (NMIBC), wherein the cancer is found only on the inner layer of the bladder wall.3 The standard therapy for NMIBC is intravesical instillation (delivery to the bladder via a catheter) of Bacillus Calmette-Guerin (BCG).4,5 BCG is a benign bacteria that induces an immune response in the bladder in proximity to the cancer cells, leading to clearance of the cancer in many patients. In ~30-40% of patients, however, BCG will fail, and in ~50% that initially respond, cancer will recur.6 About ANKTIVA The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved in killing cancer cells. By activating NK cells, ANKTIVA overcomes the tumor escape phase of clones resistant to T cells and restores memory T cell activity with resultant prolonged duration of complete response. ANKTIVA is a first-in-class IL-15 agonist IgG1 fusion complex, consisting of an IL-15 mutant (IL-15N72D) fused with an IL-15 receptor alpha, which binds with high affinity to IL-15 receptors on NK, CD4+, and CD8+ T cells. This fusion complex of ANKTIVA mimics the natural biological properties of the membrane-bound IL-15 receptor alpha, delivering IL-15 by dendritic cells and drives the activation and proliferation of NK cells with the generation of memory killer T cells that have retained immune memory against these tumor clones. The proliferation of the trifecta of these immune killing cells and the activation of trained immune memory results in immunogenic cell death, inducing a state of equilibrium with durable complete responses. ANKTIVA has improved pharmacokinetic properties, longer persistence in lymphoid tissues, and enhanced anti-tumor activity compared to native, non-complexed IL-15 in-vivo. ANKTIVA was approved by the FDA in 2024 for BCG-unresponsive non-muscle invasive bladder cancer CIS with or without papillary tumors. For more information, visit INDICATION AND IMPORTANT SAFETY INFORMATION FROM THE FDA LABEL INDICATION AND USAGE: ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. WARNINGS AND PRECAUTIONS: Risk of Metastatic Bladder Cancer with Delayed Cystectomy. Delaying cystectomy can lead to the development of muscle invasive or metastatic bladder cancer, which can be lethal. If patient with CIS do not have a complete response to treatment after a second induction course of ANKTIVA with BCG, reconsider cystectomy. DOSAGE AND ADMINISTRATION: For lntravesical Use Only. Do not administer by subcutaneous or intravenous routes. Instill intravesically only after dilution. Total time from vial puncture to the completion of the intravesical instillation should not exceed 2 hours. USE IN SPECIFIC POPULATIONS: Pregnancy: May cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. ADVERSE REACTIONS: The most common (≥15%) adverse reactions, including laboratory test abnormalities, are increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills and pyrexia. For more information about ANKTIVA, please see the Full Prescribing Information at You are encouraged to report negative side effects of prescription drugs to FDA. Visit or call 1-800-332-1088. You may also contact lmmunityBio at 1-877-ANKTIVA (1-877-265-8482) About ImmunityBio ImmunityBio is a vertically-integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The Company's range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases. For more information, visit (Founder's Vision) and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram. References: Action Bladder UK. Non-muscle invasive bladder cancer. May 2021. Available at: World Cancer Research Fund. Bladder Cancer Statistics. 2022. Available at: Aldousari S, Kassouf W. Update on the management of non-muscle invasive bladder cancer. Canadian Urological Association Journal, 4(1), 56–64. Holzbeierlein J, Bixler BR, Buckley DI, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment. J Urol. 2024;10.1097/JU.0000000000003846. Grabe-Heyne, et al. Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs. Front Oncol. 2023 Jun 2;13:1170124. doi: 10.3389/fonc.2023.1170124. Kodera A, Mohammed M, Lim P, Abdalla O, Elhadi M. The Management of Bacillus Calmette-Guérin (BCG) Failure in High-Risk Non-muscle Invasive Bladder Cancer: A Review Article. Cureus. 2023 Jun 26;15(6):e40962. doi: 10.7759/cureus.40962. PMID: 37503461; PMCID: PMC10369196. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding clinical trial data and potential results and implications to be drawn therefrom, the belief that the MHRA authorization leads to increased revenue, the expectation that the EAP as previously reported will enable access to ANKTIVA for patients across all solid tumor types who have exhausted first-line therapy including chemo, radiation or immunotherapy, the RMAT designation as previously reported and potential results therefrom and regulatory submissions in connection therewith, the belief that ALC levels and NLR levels obtained from a CBC are predictors of clinical benefit and outcomes relating to overall survival, the belief that improving ALC levels and NLR levels correlates with enhanced overall survival and clinical benefit, the belief that reversal of lymphopenia correlates with improved survival, clinical trial and expanded access program enrollment, data and potential results to be drawn therefrom, anticipated components of ImmunityBio's Cancer BioShield platform, the development of therapeutics for cancer and infectious diseases, potential benefits to patients, potential treatment outcomes for patients, the described mechanism of action and results and contributions therefrom, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents for the prevention or reversal of lymphopenia, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents across multiple tumor types and indications and for potential applications beyond oncology, potential regulatory pathways and the regulatory review process and timing thereof, the application of the Company's science and platforms to treat cancers or develop cancer vaccines, immunotherapies and cell therapies that has the potential to change the paradigm in cancer care, and ImmunityBio's approved product and investigational agents as compared to existing treatment options, and the impact of the MHRA on the Company's ex-United States go to market strategy, including in light of the recently implemented United States Most Favored Nation pricing policy on the Company's go-to-market strategy in the United Kingdom, among others. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as "anticipates," "believes," "continues," "goal," "could," "estimates," "scheduled," "expects," "intends," "may," "plans," "potential," "predicts," "indicate," "projects," "is," "seeks," "should," "will," "strategy," and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio's management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio's statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) risks and uncertainties regarding the FDA regulatory submission, filing and review process and the timing thereof, (ii) risks and uncertainties regarding regulatory submissions in foreign jurisdictions, filing and review process and the timing thereof, (iii) whether the RMAT designation will lead to an accelerated review or approval, of which there can be no assurance, (iv) risks and uncertainties regarding commercial launch execution, success and timing, (v) risks and uncertainties regarding participation and enrollment and potential results from the expanded access clinical investigation program described herein, (vi) whether clinical trials will result in registrational pathways and the risks, (vii) whether clinical trial data will be accepted by regulatory agencies, (viii) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (iv) potential delays in product availability and regulatory approvals, (x) ImmunityBio's ability to retain and hire key personnel, (xi) ImmunityBio's ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (xii) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (xiii) ImmunityBio's ability to successfully commercialize its approved product and product candidates, (xiv) ImmunityBio's ability to scale its manufacturing and commercial supply operations for its approved product and future approved products, and (xv) ImmunityBio's ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio's business are described under the heading "Risk Factors" in the Company's Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2025, and the Company's Form 10-Q filed with the SEC on May 12, 2025, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC's website at ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. View source version on Contacts ImmunityBio Contacts: Investors Hemanth Ramaprakash, PhD, MBA ImmunityBio, Inc. +1 Media Sarah Singleton ImmunityBio, Inc. +1 Sign in to access your portfolio
CBS News
02-07-2025
- CBS News
CHP officer dies after medical incident leads to single-car line-of-duty crash
An officer with the California Highway Patrol died Wednesday after suffering from a medical emergency following an arrest in Culver City, authorities said, leading to a single-car crash. CHP Commissioner Sean Duryee announced during a news conference that Officer Miguel Cano, 34, of Moreno Valley, was pronounced dead at about 1:40 a.m. His cause of death is still unclear as of Wednesday morning. "We do not think the crash was consistent with fatal injuries," Duryee said. Miguel Cano, 34 of Moreno Valley, died after experiencing a medical emergency while behind the wheel of a CHP vehicle, leading to a crash on Wednesday, July 2, 2025. California Highway Patrol Duryee said he and his partner arrested a person on suspicion of DUI and were transporting them when Cano told his partner that he wasn't feeling well. His partner responded by saying that he didn't look well, and Cano lost consciousness soon after. After losing consciousness, Cano crashed the vehicle carrying his partner and the suspect into a tree, Duryee confirmed. At the scene, first responders administered Narcan on Cano as a precaution, Duryee said. He added that it's not believed that Cano's death was related to potential exposure to drugs. A CHP officer died following a single-car crash in Culver City just after midnight Wednesday morning. A firearm, a substance that appeared to be cocaine and drug paraphernalia were found in the suspect's vehicle after the arrest. No additional information relating to Cano's death was immediately made available. Duryee said Cano was married and was with the CHP for two years, having graduated from the academy in the fall of 2023. "This young man, he's a hero," Druyee said. "He's out there doing what we ask these officers to do." The Culver City Police Department said the crash occurred at about 12:30 a.m. in the area of Green Valley Circle and Bristol Parkway. The CHP initially described the incident as a single-car crash that injured three. The other two, including Cano's partner, suffered minor injuries. Images from the scene show an SUV with CHP markings with damage to the front. The SUV was off of the main road and on a dirt patch near several trees; it wasn't clear as of 6 a.m. whether the vehicle collided with a tree. Authorities asked the public to avoid the area between Green Valley Circle to Uplander Way as investigations played out. All roads were reopened by 10 a.m.
